Advancing Treatment Evaluation With Surrogate End Points in MPNs

Kapila Viges, of the MPN Research Foundation, and John Mascarenhas, MD, of the Icahn School of Medicine, discuss the role of surrogate end points in multiple myeloma clinical trials. Since overall survival data can take years to mature, researchers rely on early surrogate markers to assess treatment efficacy. In this conversation, Viges and Dr. Mascarenhas explore whether spleen volume reduction or symptom burden may serve as more reliable indicators of therapeutic benefit. They also discuss other potential surrogate end points for myeloma clinical trials.